APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningioma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Meningioma Drug Industry Growth and Trends Forecast to 2032

22 December 2025104 pages

Choose your research edition.

Industry ResearchMeningioma Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningioma Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Meningioma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningioma Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningioma Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Meningioma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningioma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Meningioma Drug include Arno Therapeutics Inc, Boehringer Ingelheim GmbH, Genentech Inc, Merck KGaA, Ono Pharmaceutical Co Ltd, Pharma Mar SA, Progenics Pharmaceuticals Inc, AstraZeneca Plc and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Meningioma Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Meningioma Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Meningioma Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Meningioma Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Meningioma Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Meningioma Drug Market by Company

Arno Therapeutics Inc

Boehringer Ingelheim GmbH

Genentech Inc

Merck KGaA

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Progenics Pharmaceuticals Inc

AstraZeneca Plc

GlaxoSmithKline Plc

Eli Lilly and Co

Merck & Co Inc

Novartis AG

Meningioma Drug Segment by Type

Avelumab

AR-42

Afatinib Dimaleate

Abemaciclib

Others

Meningioma Drug Segment by Application

Hospital

Clinic

Others

Meningioma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningioma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningioma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningioma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Meningioma Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Meningioma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Avelumab Table 2. Major Company of AR-42 Table 3. Major Company of Afatinib Dimaleate Table 4. Major Company of Abemaciclib Table 5. Major Company of Others Table 6. Global Meningioma Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Meningioma Drug Sales by Type (2021-2026) & (k units) Table 8. Global Meningioma Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Meningioma Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Meningioma Drug Price by Type (2021-2026) & (US$/unit) Table 12. Global Meningioma Drug Sales by Type (2027-2032) & (k units) Table 13. Global Meningioma Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Meningioma Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Meningioma Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Meningioma Drug Price by Type (2027-2032) & (US$/unit) Table 17. North America Meningioma Drug Sales by Type (2021-2026) & (k units) Table 18. North America Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Meningioma Drug Sales by Type (2021-2026) & (k units) Table 20. Europe Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Meningioma Drug Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Meningioma Drug Sales by Type (2021-2026) & (k units) Table 24. Latin America Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Meningioma Drug Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Meningioma Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Meningioma Drug Industry Trends Table 28. Meningioma Drug Industry Drivers Table 29. Meningioma Drug Industry Opportunities and Challenges Table 30. Meningioma Drug Industry Restraints Table 31. Global Meningioma Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Meningioma Drug Revenue Market Share by Company (2021-2026) Table 33. Global Meningioma Drug Sales by Company (2021-2026) & (k units) Table 34. Global Meningioma Drug Sales Share by Company (2021-2026) Table 35. Global Meningioma Drug Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Meningioma Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Meningioma Drug Major Company Production Sites and Headquarters Table 38. Global Meningioma Drug Company, Product Type & Application Table 39. Global Meningioma Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Meningioma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Meningioma Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Meningioma Drug Sales by Region (2021-2026) & (k units) Table 44. Global Meningioma Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Meningioma Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Meningioma Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Meningioma Drug Sales by Region (2027-2032) & (k units) Table 49. Global Meningioma Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Meningioma Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Meningioma Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Meningioma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Meningioma Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Meningioma Drug Sales by Application (2021-2026) & (k units) Table 55. Global Meningioma Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Meningioma Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Meningioma Drug Price by Application (2021-2026) & (US$/unit) Table 59. Global Meningioma Drug Sales by Application (2027-2032) & (k units) Table 60. Global Meningioma Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Meningioma Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Meningioma Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Meningioma Drug Price by Application (2027-2032) & (US$/unit) Table 64. North America Meningioma Drug Sales by Application (2021-2026) & (k units) Table 65. North America Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Meningioma Drug Sales by Application (2021-2026) & (k units) Table 67. Europe Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Meningioma Drug Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Meningioma Drug Sales by Application (2021-2026) & (k units) Table 71. Latin America Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Meningioma Drug Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Meningioma Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Arno Therapeutics Inc Company Information Table 75. Arno Therapeutics Inc Business Overview Table 76. Arno Therapeutics Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Arno Therapeutics Inc Meningioma Drug Product Portfolio Table 78. Arno Therapeutics Inc Recent Development Table 79. Boehringer Ingelheim GmbH Company Information Table 80. Boehringer Ingelheim GmbH Business Overview Table 81. Boehringer Ingelheim GmbH Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio Table 83. Boehringer Ingelheim GmbH Recent Development Table 84. Genentech Inc Company Information Table 85. Genentech Inc Business Overview Table 86. Genentech Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Genentech Inc Meningioma Drug Product Portfolio Table 88. Genentech Inc Recent Development Table 89. Merck KGaA Company Information Table 90. Merck KGaA Business Overview Table 91. Merck KGaA Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Merck KGaA Meningioma Drug Product Portfolio Table 93. Merck KGaA Recent Development Table 94. Ono Pharmaceutical Co Ltd Company Information Table 95. Ono Pharmaceutical Co Ltd Business Overview Table 96. Ono Pharmaceutical Co Ltd Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio Table 98. Ono Pharmaceutical Co Ltd Recent Development Table 99. Pharma Mar SA Company Information Table 100. Pharma Mar SA Business Overview Table 101. Pharma Mar SA Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Pharma Mar SA Meningioma Drug Product Portfolio Table 103. Pharma Mar SA Recent Development Table 104. Progenics Pharmaceuticals Inc Company Information Table 105. Progenics Pharmaceuticals Inc Business Overview Table 106. Progenics Pharmaceuticals Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio Table 108. Progenics Pharmaceuticals Inc Recent Development Table 109. AstraZeneca Plc Company Information Table 110. AstraZeneca Plc Business Overview Table 111. AstraZeneca Plc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. AstraZeneca Plc Meningioma Drug Product Portfolio Table 113. AstraZeneca Plc Recent Development Table 114. GlaxoSmithKline Plc Company Information Table 115. GlaxoSmithKline Plc Business Overview Table 116. GlaxoSmithKline Plc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. GlaxoSmithKline Plc Meningioma Drug Product Portfolio Table 118. GlaxoSmithKline Plc Recent Development Table 119. Eli Lilly and Co Company Information Table 120. Eli Lilly and Co Business Overview Table 121. Eli Lilly and Co Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Eli Lilly and Co Meningioma Drug Product Portfolio Table 123. Eli Lilly and Co Recent Development Table 124. Merck & Co Inc Company Information Table 125. Merck & Co Inc Business Overview Table 126. Merck & Co Inc Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Merck & Co Inc Meningioma Drug Product Portfolio Table 128. Merck & Co Inc Recent Development Table 129. Novartis AG Company Information Table 130. Novartis AG Business Overview Table 131. Novartis AG Meningioma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Novartis AG Meningioma Drug Product Portfolio Table 133. Novartis AG Recent Development Table 134. North America Meningioma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. North America Meningioma Drug Sales by Country (2021-2026) & (k units) Table 136. North America Meningioma Drug Sales Market Share by Country (2021-2026) Table 137. North America Meningioma Drug Sales Forecast by Country (2027-2032) & (k units) Table 138. North America Meningioma Drug Sales Market Share Forecast by Country (2027-2032) Table 139. North America Meningioma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. North America Meningioma Drug Market Size by Country (2021-2026) & (US$ Million) Table 141. North America Meningioma Drug Market Share by Country (2021-2026) Table 142. North America Meningioma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. North America Meningioma Drug Market Share Forecast by Country (2027-2032) Table 144. Europe Meningioma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Europe Meningioma Drug Sales by Country (2021-2026) & (k units) Table 146. Europe Meningioma Drug Sales Market Share by Country (2021-2026) Table 147. Europe Meningioma Drug Sales Forecast by Country (2027-2032) & (k units) Table 148. Europe Meningioma Drug Sales Market Share Forecast by Country (2027-2032) Table 149. Europe Meningioma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Europe Meningioma Drug Market Size by Country (2021-2026) & (US$ Million) Table 151. Europe Meningioma Drug Market Share by Country (2021-2026) Table 152. Europe Meningioma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Europe Meningioma Drug Market Share Forecast by Country (2027-2032) Table 154. Asia-Pacific Meningioma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 155. Asia-Pacific Meningioma Drug Sales by Country (2021-2026) & (k units) Table 156. Asia-Pacific Meningioma Drug Sales Market Share by Country (2021-2026) Table 157. Asia-Pacific Meningioma Drug Sales Forecast by Country (2027-2032) & (k units) Table 158. Asia-Pacific Meningioma Drug Sales Market Share Forecast by Country (2027-2032) Table 159. Asia-Pacific Meningioma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Asia-Pacific Meningioma Drug Market Size by Country (2021-2026) & (US$ Million) Table 161. Asia-Pacific Meningioma Drug Market Share by Country (2021-2026) Table 162. Asia-Pacific Meningioma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Asia-Pacific Meningioma Drug Market Share Forecast by Country (2027-2032) Table 164. Latin America Meningioma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 165. Latin America Meningioma Drug Sales by Country (2021-2026) & (k units) Table 166. Latin America Meningioma Drug Sales Market Share by Country (2021-2026) Table 167. Latin America Meningioma Drug Sales Forecast by Country (2027-2032) & (k units) Table 168. Latin America Meningioma Drug Sales Market Share Forecast by Country (2027-2032) Table 169. Latin America Meningioma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Latin America Meningioma Drug Market Size by Country (2021-2026) & (US$ Million) Table 171. Latin America Meningioma Drug Market Share by Country (2021-2026) Table 172. Latin America Meningioma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Latin America Meningioma Drug Market Share Forecast by Country (2027-2032) Table 174. Middle East and Africa Meningioma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 175. Middle East and Africa Meningioma Drug Sales by Country (2021-2026) & (k units) Table 176. Middle East and Africa Meningioma Drug Sales Market Share by Country (2021-2026) Table 177. Middle East and Africa Meningioma Drug Sales Forecast by Country (2027-2032) & (k units) Table 178. Middle East and Africa Meningioma Drug Sales Market Share Forecast by Country (2027-2032) Table 179. Middle East and Africa Meningioma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Middle East and Africa Meningioma Drug Market Size by Country (2021-2026) & (US$ Million) Table 181. Middle East and Africa Meningioma Drug Market Share by Country (2021-2026) Table 182. Middle East and Africa Meningioma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Middle East and Africa Meningioma Drug Market Share Forecast by Country (2027-2032) Table 184. Key Raw Materials Table 185. Raw Materials Key Suppliers Table 186. Meningioma Drug Distributors List Table 187. Meningioma Drug Customers List Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources Table 191. Primary Sources List of Figures Figure 1. Meningioma Drug Image Figure 2. Global Meningioma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningioma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Meningioma Drug Sales (2021-2032) & (k units) Figure 5. Avelumab Image Figure 6. Global Avelumab Sales YoY Growth (2021-2032) & (k units) Figure 7. AR-42 Image Figure 8. Global AR-42 Sales YoY Growth (2021-2032) & (k units) Figure 9. Afatinib Dimaleate Image Figure 10. Global Afatinib Dimaleate Sales YoY Growth (2021-2032) & (k units) Figure 11. Abemaciclib Image Figure 12. Global Abemaciclib Sales YoY Growth (2021-2032) & (k units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Meningioma Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Meningioma Drug Market Share by Type 2025 VS 2032 Figure 17. North America Meningioma Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Meningioma Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Meningioma Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Meningioma Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Meningioma Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Meningioma Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Meningioma Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Meningioma Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Meningioma Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Meningioma Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Meningioma Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Meningioma Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Meningioma Drug Market Share by Application 2025 VS 2032 Figure 37. North America Meningioma Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Meningioma Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Meningioma Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Meningioma Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Meningioma Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Meningioma Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Meningioma Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Meningioma Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Meningioma Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Meningioma Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Meningioma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Meningioma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Meningioma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Meningioma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Meningioma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Meningioma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Meningioma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Meningioma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Meningioma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Meningioma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Meningioma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Meningioma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Meningioma Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Meningioma Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Avelumab
  • AR-42
  • Afatinib Dimaleate
  • Abemaciclib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Arno Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Genentech Inc
  • Merck KGaA
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Merck & Co Inc
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningioma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Meningioma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Meningioma Drug Market by Type
  6. 1.3.1 Avelumab
  7. 1.3.2 AR-42
  8. 1.3.3 Afatinib Dimaleate
  9. 1.3.4 Abemaciclib
  10. 1.3.5 Others
  11. 1.4 Global Meningioma Drug Market Size by Type
  12. 1.4.1 Global Meningioma Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Meningioma Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Meningioma Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Meningioma Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Meningioma Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Meningioma Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Meningioma Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Meningioma Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Meningioma Drug Industry Trends
  2. 2.2 Meningioma Drug Industry Drivers
  3. 2.3 Meningioma Drug Industry Opportunities and Challenges
  4. 2.4 Meningioma Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Meningioma Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Meningioma Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Meningioma Drug Price (2021-2026)
  4. 3.4 Global Meningioma Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Meningioma Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Meningioma Drug Company, Product Type & Application
  7. 3.7 Global Meningioma Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Meningioma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Meningioma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Meningioma Drug Tier 1, Tier 2, and Tier 3
4 Meningioma Drug Regional Status and Outlook
  1. 4.1 Global Meningioma Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Meningioma Drug Historic Market Size by Region
  3. 4.2.1 Global Meningioma Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Meningioma Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Meningioma Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Meningioma Drug Forecasted Market Size by Region
  7. 4.3.1 Global Meningioma Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Meningioma Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Meningioma Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Meningioma Drug by Application
  1. 5.1 Meningioma Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Meningioma Drug Market Size by Application
  6. 5.2.1 Global Meningioma Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Meningioma Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Meningioma Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Meningioma Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Meningioma Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Meningioma Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Meningioma Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Meningioma Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Arno Therapeutics Inc
  2. 6.1.1 Arno Therapeutics Inc Company Information
  3. 6.1.2 Arno Therapeutics Inc Business Overview
  4. 6.1.3 Arno Therapeutics Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Arno Therapeutics Inc Meningioma Drug Product Portfolio
  6. 6.1.5 Arno Therapeutics Inc Recent Developments
  7. 6.2 Boehringer Ingelheim GmbH
  8. 6.2.1 Boehringer Ingelheim GmbH Company Information
  9. 6.2.2 Boehringer Ingelheim GmbH Business Overview
  10. 6.2.3 Boehringer Ingelheim GmbH Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim GmbH Meningioma Drug Product Portfolio
  12. 6.2.5 Boehringer Ingelheim GmbH Recent Developments
  13. 6.3 Genentech Inc
  14. 6.3.1 Genentech Inc Company Information
  15. 6.3.2 Genentech Inc Business Overview
  16. 6.3.3 Genentech Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Genentech Inc Meningioma Drug Product Portfolio
  18. 6.3.5 Genentech Inc Recent Developments
  19. 6.4 Merck KGaA
  20. 6.4.1 Merck KGaA Company Information
  21. 6.4.2 Merck KGaA Business Overview
  22. 6.4.3 Merck KGaA Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck KGaA Meningioma Drug Product Portfolio
  24. 6.4.5 Merck KGaA Recent Developments
  25. 6.5 Ono Pharmaceutical Co Ltd
  26. 6.5.1 Ono Pharmaceutical Co Ltd Company Information
  27. 6.5.2 Ono Pharmaceutical Co Ltd Business Overview
  28. 6.5.3 Ono Pharmaceutical Co Ltd Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Ono Pharmaceutical Co Ltd Meningioma Drug Product Portfolio
  30. 6.5.5 Ono Pharmaceutical Co Ltd Recent Developments
  31. 6.6 Pharma Mar SA
  32. 6.6.1 Pharma Mar SA Company Information
  33. 6.6.2 Pharma Mar SA Business Overview
  34. 6.6.3 Pharma Mar SA Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pharma Mar SA Meningioma Drug Product Portfolio
  36. 6.6.5 Pharma Mar SA Recent Developments
  37. 6.7 Progenics Pharmaceuticals Inc
  38. 6.7.1 Progenics Pharmaceuticals Inc Company Information
  39. 6.7.2 Progenics Pharmaceuticals Inc Business Overview
  40. 6.7.3 Progenics Pharmaceuticals Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Progenics Pharmaceuticals Inc Meningioma Drug Product Portfolio
  42. 6.7.5 Progenics Pharmaceuticals Inc Recent Developments
  43. 6.8 AstraZeneca Plc
  44. 6.8.1 AstraZeneca Plc Company Information
  45. 6.8.2 AstraZeneca Plc Business Overview
  46. 6.8.3 AstraZeneca Plc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 AstraZeneca Plc Meningioma Drug Product Portfolio
  48. 6.8.5 AstraZeneca Plc Recent Developments
  49. 6.9 GlaxoSmithKline Plc
  50. 6.9.1 GlaxoSmithKline Plc Company Information
  51. 6.9.2 GlaxoSmithKline Plc Business Overview
  52. 6.9.3 GlaxoSmithKline Plc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 GlaxoSmithKline Plc Meningioma Drug Product Portfolio
  54. 6.9.5 GlaxoSmithKline Plc Recent Developments
  55. 6.10 Eli Lilly and Co
  56. 6.10.1 Eli Lilly and Co Company Information
  57. 6.10.2 Eli Lilly and Co Business Overview
  58. 6.10.3 Eli Lilly and Co Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly and Co Meningioma Drug Product Portfolio
  60. 6.10.5 Eli Lilly and Co Recent Developments
  61. 6.11 Merck & Co Inc
  62. 6.11.1 Merck & Co Inc Company Information
  63. 6.11.2 Merck & Co Inc Business Overview
  64. 6.11.3 Merck & Co Inc Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck & Co Inc Meningioma Drug Product Portfolio
  66. 6.11.5 Merck & Co Inc Recent Developments
  67. 6.12 Novartis AG
  68. 6.12.1 Novartis AG Company Information
  69. 6.12.2 Novartis AG Business Overview
  70. 6.12.3 Novartis AG Meningioma Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Novartis AG Meningioma Drug Product Portfolio
  72. 6.12.5 Novartis AG Recent Developments
7 North America by Country
  1. 7.1 North America Meningioma Drug Sales by Country
  2. 7.1.1 North America Meningioma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Meningioma Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Meningioma Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Meningioma Drug Market Size by Country
  6. 7.2.1 North America Meningioma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Meningioma Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Meningioma Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Meningioma Drug Sales by Country
  2. 8.1.1 Europe Meningioma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Meningioma Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Meningioma Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Meningioma Drug Market Size by Country
  6. 8.2.1 Europe Meningioma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Meningioma Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Meningioma Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Meningioma Drug Sales by Country
  2. 9.1.1 Asia-Pacific Meningioma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Meningioma Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Meningioma Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Meningioma Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Meningioma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Meningioma Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Meningioma Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Meningioma Drug Sales by Country
  2. 10.1.1 South America Meningioma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Meningioma Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Meningioma Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Meningioma Drug Market Size by Country
  6. 10.2.1 South America Meningioma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Meningioma Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Meningioma Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Meningioma Drug Sales by Country
  2. 11.1.1 Middle East and Africa Meningioma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Meningioma Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Meningioma Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Meningioma Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Meningioma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Meningioma Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Meningioma Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Meningioma Drug Value Chain Analysis
  2. 12.1.1 Meningioma Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Meningioma Drug Production Mode & Process
  7. 12.2 Meningioma Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Meningioma Drug Distributors
  10. 12.2.3 Meningioma Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst